Cargando…
Effects of Sodium‐Glucose Cotransporter 2 Inhibitors on 24‐Hour Ambulatory Blood Pressure: A Systematic Review and Meta‐Analysis
BACKGROUND: Sodium‐glucose cotransporter 2 (SGLT2) inhibitors are a novel class of antihyperglycemic agents that improve glycemic control by increasing glycosuria. Additional benefits beyond glucose lowering include significant improvements in seated clinic blood pressure (BP), partly attributed to...
Autores principales: | Baker, William L., Buckley, Leo F., Kelly, Michael S., Bucheit, John D., Parod, Eric D., Brown, Roy, Carbone, Salvatore, Abbate, Antonio, Dixon, Dave L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5524106/ https://www.ncbi.nlm.nih.gov/pubmed/28522675 http://dx.doi.org/10.1161/JAHA.117.005686 |
Ejemplares similares
-
Sodium-Glucose Cotransporter-2 Inhibition Benefits in Cardiorenal Risk in Men and Women
por: Pruett, Jacob E, et al.
Publicado: (2022) -
Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Pneumonia and Septic Shock
por: Li, Hang-Long, et al.
Publicado: (2022) -
Early Enteral Nutrition within 24 Hours or between 24 and 72 Hours for Acute Pancreatitis: Evidence Based on 12 RCTs
por: Li, Xueping, et al.
Publicado: (2014) -
Glucagon-like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter Inhibitors for Treatment of T2DM
por: McKee, Alexis, et al.
Publicado: (2020) -
Potential for sodium-glucose cotransporter-2 inhibitors in the management of metabolic syndrome: A systematic review and meta-analysis
por: Olagunju, Abdulbaril, et al.
Publicado: (2022)